This is the first study to examine the outcomes in 54 patients with hematologic malignancies who received an HLA-matched related donor bone marrow (BM, n ¼ 42) or GCSF-mobilized peripheral blood stem cells (PBSC, n ¼ 12) following identical nonmyeloablative conditioning with the intention of induction of mixed chimerism (MC) followed by prophylactic donor leukocyte infusion (pDLI) to convert MC to full donor chimerism (FDC) and capture a graft-versus-tumor effect without clinical graft-versushost disease (GVHD). Neutrophil and platelet recovery were faster and transfusion requirement was less in PBSC recipients (Po0.05). A total of 48% of BMT recipients achieved FDC with a median conversion time of 84 days, including 13 following pDLI. In contrast, 83% (P ¼ 0.04) in the PBSC group had spontaneous FDC at a median of 14 days, precluding the administration of pDLI. There was no significant difference in the incidences of acute or chronic GVHD, though the rates of chronic GVHD were considerably higher in PBSC group than in the BM group (6/7, 86% vs 10/24, 42%). CD4 and CD8 T-cell recovery was faster in PBSC recipients. In PBSC recipients, a higher number of CD34 þ cells was associated with increased rates of severe, grade III-IV acute GVHD.
Introduction
Major changes in the source of hematopoietic stem cells (HSC) have occurred over the last decade with PBSCT emerging as a preferred alternative to BMT for treatment of hematologic malignancies. PBSC allografts contain an approximately fourfold greater number of CD34 þ cells and 1 log more lymphocytes than bone marrow grafts. 1,2 These two sources of allografts also differ in their reconstitutive and immunologic characteristics, which seem to be based on the proportion of early pluripotent and self-renewing stem cells to lineage-committed late progenitor cells, functional characteristics of T cells, and on the number and type of accompanying accessory cells. Multiple prospective and retrospective studies, all of which used myeloablative conditioning therapy, have compared outcomes after PBSCT with outcomes after BMT in the HLAmatched related and unrelated donor setting. [3] [4] [5] [6] [7] [8] [9] [10] While all studies demonstrated faster hematopoietic recovery after PBSCT, data on other end points such as acute or chronic GVHD, relapse and survival are less consistent. In all except for the EBMT study, 11 the cumulative incidence of acute GVHD was not statistically different with the use of GCSF-mobilized PBSC or BM grafts for hematopoietic reconstitution. Some studies did not demonstrate a significant difference in chronic GVHD, 4, 6 while others indicated a significantly higher incidence of chronic GVHD with PBSCT. 3, 5, 7, 9, 10 According to some studies, the diseasefree survival rates were higher after PBSCT, especially in patients with advanced-stage disease (CML beyond first chronic phase and acute leukemia in second remission). In nonmyeloablative HSCT, graft-versus-tumor (GVT) effects have replaced myeloablative therapy as the conceptual basis for treating underlying malignancies. [12] [13] [14] [15] [16] [17] However, there has not been a single comparative study of the outcomes of PBSCT vs BMT following reduced intensity/ nonmyeloablative conditioning.
It has been demonstrated that mixed chimerism (MC) can be achieved in mice across full MHC barriers after both myeloablative and nonmyeloablative preparative regimens. When nontolerant donor leukocyte infusion (DLI) are given to these mixed chimeras several weeks following BMT, they convert to full donor-type chimeras as a result of a potent lymphohematopoietic graft-versus-host reactions, but GVHD does not occur. 18, 19 Furthermore, delayed infusions of donor leukocytes mediate powerful antitumor effects in murine-mixed chimeras 20 without causing GVHD. Based on this we have performed HLA-matched donor transplants in patients with mostly chemotherapy-refractory hematologic malignancies using a nonmyeloablative preparative regimen consisting of cyclophosphamide, peri-transplant anti-thymocyte globulin, thymic irradiation, cyclosporine and delayed prophylactic donor leukocyte infusion (pDLI). While we demonstrated that establishment of initial MC is possible following nonmyeloablative stem-cell transplantation and that pDLI can often lead to successful conversion to full donor chimerism (FDC), thereby capturing striking durable GVT effect with little or no GVHD, we experienced, unlike in murine models, a relatively high rate of GVHD following stem-cell infusion or after DLI. 21 It is possible that (1) antithymocyte globulin (ATG)-mediated T-cell depletion was not as complete in our patients as it was in mice using CD4 and CD8 monoclonal antibodies and thereby induced either clinical GVHD after BMT or a subclinical GVHD, which was accentuated when nontolerant pDLIs were given and/ or (2) the proinflammatory conditions (upregulation of cell adhesion molecules and various cytokines and chemokines) that play a role in the pathogenesis of GVHD are different in heavily pretreated patients and not as short lived in duration as in animal models.
The primary objective of this nonrandomized, retrospective study was to compare the outcomes of patients who received either BMT or PBSCT following the same nonmyeloablative regimen. Since the clinical outcomes following HSCT can be influenced by the composition of the graft, we performed flow cytometry (FCM) analysis to determine the number of CD34 þ progenitor cells, CD4 cells, CD8 cells, CD16/CD56 þ NK cells and CD19 þ B cells in the grafts and examined the impact on transplant outcomes.
Patients and methods
Fifty-four patients with advanced hematologic malignancies, including 15 who relapsed after autologous stem-cell transplant (Au-SCT), received an HLA-matched (at A, B and DR loci) related donor BMT (n ¼ 42) or PBSCT (n ¼ 12) between 1997 and 2004 based on a nonmyeloablative MC protocol conducted at the Massachusetts General Hospital in Boston, USA. Patients showing no response to chemotherapy after diagnosis or at the time of relapse were considered to have treatment-refractory disease; those showing evidence of response were considered to have chemosensitive disease and those who underwent stem-cell transplant without being treated at the time of relapse were said to have untreated relapse at the time of transplantation. Thirty-seven BM recipients had treatment-refractory disease (16 in the pDLI group and 21 in the non-pDLI group), two had chemosensitive disease and three had untreated relapse compared to the PBSC recipients where six had treatment-refractory disease, four had chemosensitive disease and two had untreated relapse.
Patient characteristics
The diagnosis, age and disease characteristics for the 54 recipients are shown in Table 1 . Eligibility criteria included Eastern Cooperative Oncology Group performance status of 0, 1 or 2; age p65 years, and adequate organ function. Patients and their donors were typed for HLA-A and HLA-B using standard serologic techniques and for HLA-DR and -DQ using sequence-specific primer, or sequence-specific oligonucleotide probe analyses.
Treatment protocol
As shown in Figure 1 , nonmyeloablative conditioning therapy consisted of cyclophosphamide 50 mg/kg per day, administered intravenously on days -6 or -5 through -3; thymic irradiation (700 cGy) given on day -1 in patients who had not received previous mediastinal radiotherapy; antithymocyte globulin (equine ATG) 15-30 mg/kg on days -2, À1 and þ 1 or -1, þ 1, þ 3 and þ 5 and cyclosporine beginning day -1 (5 mg/kg daily intravenously, reduced to 3 mg/kg on day þ 4, switched to oral administration when No. of prior therapies 3 (1-7) 3 (1-6) No. of previous auto-transplant 13 2 Abbreviations: F ¼ female; M ¼ male. tolerated at a dose of 6 mg/kg every 12 h), then tapered to discontinuation by approximately day 35 in the absence of GVHD.
Bone marrow and peripheral blood stem-cell transplantation A target number of 3 Â 10 8 nucleated cells (NCs) per kg of recipient body weight was collected by marrow aspiration in the operating room from donors under spinal, epidural or general anesthesia. All donors of PBSCs were treated with GCSF, 10 mg/kg per day, administered subcutaneously, and a target number of X2 Â 10 6 CD34 þ cells per kg was collected after GCSF stimulation for a total of 5-6 days. FCM analysis was done on the available stem-cell inoculums (BM, n ¼ 19; PBSC, n ¼ 11) to determine the
þ NK cells and CD19 þ B cells. These cell doses are shown in Table 2 .
Donor leukocyte collection and infusion
In the absence of clinically evident GVHD or increasing T-cell chimerism, patients were eligible for pDLI, beginning on day þ 35 post-transplantation in an effort to convert their mixed chimeric state to a state of full donor hematopoiesis. Unmobilized donor leukocytes were obtained by leukapheresis using a COBE Spectra cell separator (Cobe Laboratories, Lakewood, CO, USA) according to the manufacturer's instructions. Pheresis durations were 120-240 min and yielded a median of 
Analyses of chimerism
Analyses of microsatellite variable number of tandem repeat (VNTR) or short tandem repeat (STR) markers were performed on peripheral blood leukocytes from the patients and their donors prior to BMT. Each assay included mixtures of pretransplant donor and recipient DNA at different ratios, which were used to estimate the percentage of donor and/or recipient cells present in the post-transplant samples. For early patients, CD3-enriched and CD3-depleted populations were isolated from the peripheral blood using MACS beads (Miltenyi Biotec, Sunnyvale, CA, USA). Weekly microsatellite analyses were performed on peripheral blood leukocytes beginning on day þ 7 through day þ 100 post-transplant and on days þ 28 and þ 100 on BM aspirate samples.
Disease assessment
At approximately day þ 100 post-BMT, all evaluable patients underwent restaging evaluations, including CT scans of chest, abdomen and pelvis, a gallium scan when applicable and BM aspirate and biopsy. Patients having no evidence of disease based on these studies were determined to be in complete remission (CR), and those having more than 50% reduction in measurable disease were considered to have achieved a partial remission (PR). Durable remission was defined as absence of recurrent disease, or absence of progression in cases of PR, lasting more than or equal to a year.
Statistical analysis
Descriptive statistics are summarized as a percentage or as the median and range where appropriate. Comparison between groups of the analyzed parameters was performed using the Fisher's exact test. A P-value of o0.05 was considered significant. Two-tailed Student's t-tests for comparisons of the medians were performed for evaluation of the differences in the numbers of different cell subsets between the BM and PBSC groups. Overall survival and progression-free survival (PFS) were calculated using the Kaplan-Meier method.
Results

Graft content
The cell composition of GCSF-mobilized PBSC (n ¼ 11) and steady-state BM allografts (n ¼ 19) differed significantly ( Table 2 ). The median NC dose was approximately five times higher in the PBSC group than in the BM group (Po0.0001). PBSC infusions contained three to four times more CD34 þ cells than did BM (P ¼ 0.0042). The infused numbers of all cell subpopulations including CD3 þ T cells, CD4, CD8, NK and B cells were also significantly higher (4-to 20-fold) in the PBSC group compared to the BM group (CD3 þ T cells, Po0.0001;
Time to engraftment and transfusion requirements The median times-to-neutrophil engraftment (ANC40.5 Â 10 9 /l) was 12 days (range, [11] [12] [13] [14] in the PBSC group compared to 14 days (range, 9-69) in the BM group (P ¼ NS). Platelet engraftment (420 Â 10 9 /l) in the PBSC group occurred at a median of 13 days (range, 6-20) compared to 14 days (range, 7-96) in the BM group (P ¼ NS). Fewer patients required platelet and red cell transfusion in the PBSC group (8%) compared to the BM group (81%) (Po0.05).
Chimerism conversion
The fate of donor T-cell chimerism for both BM and PBSC groups is shown in Figure 2 . In the BMT group, 16 patients (38%) who had stable MC received a pDLI beginning 5 weeks post-BMT, while 26 patients did not receive pDLI, either because of GVHD or early relapse. In the latter case, a tDLI was administered. Twenty of the BMT recipients (48%) achieved either FDC (499% donor T cells) or near-FDC (490% donor T cells): seven converted spontaneously after the BMT, two following tDLI and 11 after pDLI; five patients had stable MC, including four spontaneously after BMT and one following pDLI. In contrast, 10 out of 12 patients (83%; P ¼ 0.04) in the PBSC group had spontaneous development of near-complete or FDC at a median time of 14 (range, 7-42) days posttransplant and one patient had stable MC.
Loss of graft
All recipients of both BM and PBSC had initial MC. In the BM group, 14 out of 38 evaluable patients (37%) ultimately lost the graft despite DLI(s) at a median of 48 (range, 19-144) days post-transplant, including 4 after pDLI and 10 following early and late tDLIs. In contrast, only 1 of 12 patients (8%) in the PBSC group lost the allograft despite multiple DLIs (P ¼ 0.078; Figure 2 ).
Rapid conversion to FDC in the PBSC group
The median conversion time to FDC, both spontaneously and following prophylactic and tDLI, was 84 (range, 35-100) days post-BMT. The conversion to FDC was a gradual process following pDLI, as shown in Figure 3a . In contrast, in the PBSC group, all patients had very high donor chimerism immediately after transplantation, and 83% achieved FDC in both CD3 þ (lymphoid) and CD3 À (myeloid) populations at a median of 14 (range, 7-42) days post-transplant (Figure 3b) , which precluded the administration of pDLI.
GVHD
Twenty patients in the BMT group (48%) developed
Xgrade II acute GVHD, including 13 after the BMT (Grade II, n ¼ 9; Grade III, n ¼ 2; Grade IV, n ¼ 2) and seven following pDLI (grade II, n ¼ 2; grade III, n ¼ 1; grade IV, n ¼ 4) compared with the PBSC group, in which nine recipients (75%) developed Xgrade II acute GVHD (grade II, n ¼ 3; grade III, n ¼ 2; grade IV, n ¼ 4) within 5 to 6 weeks post-PBSCT without pDLI, but the difference was not statistically significant. When analyzed according to achievement of FDC, the two groups were similar in terms of the incidence of Xgrade II acute GVHD with 15 out of 20 patients (75%) in the BMT group and 8 out 10 (80%) in Figure 2 The fate of donor T-cell chimerism at 100 days post-transplant for both BM and PBSC recipients as determined by weekly analyses of microsatellite VNTR or STR performed on peripheral blood leukocytes beginning on day þ 7 through day þ 100 post-HSCT. HSCT, hematopoietic SCT; STR, short tandem repeat; VNTR, variable number of tandem repeat.
the PBSCT group developing GVHD. The rates of severe, grade III or IV acute GVHD in the fully chimeric patients were higher in the PBSC group compared to the BM group (60 vs 30%), but this was not statistically significant. The cumulative incidence of chronic GVHD was considerably higher in the PBSC group than in the BM group (6/7, 86% vs 10/24, 42%; P ¼ 0.08), and a trend toward an increased incidence of chronic GVHD in the PBSC recipients persisted when patients with FDC only were analyzed (PBSC: 5/5, 100% vs BM: 9/13, 69%).
Influence of Au-HSCT on donor chimerism Out of 13 patients in the BM group who previously underwent an autologous stem-cell transplant, 10 achieved FDC (77%), 2 had sustained MC and 1 lost the allograft. In contrast, only 9 of 29 BM recipients (31%; P ¼ 0.008) who had not had a previous autologous stem-cell transplant achieved FDC, which suggests that prior Au-HSCT promotes donor engraftment. In the PBSC group, only 2 out of 10 patients (20%) who achieved FDC had a previous Au-HSCT in contrast to the BM group where 10 out of 20 recipients (50%) achieving FDC had received a previous Au-HSCT, indicating that following the same nonmyeloablative conditioning regimen, PBSC recipients are more likely than BM recipients to develop FDC without prior Au-SCT.
Impact of cell dose on clinical outcome
The clinical outcomes following SCT can be influenced by the source of stem cells and the total numbers of accessory cellular subpopulations within the graft. We determined the numbers of different cell subsets in allografts (BMT, n ¼ 19; PBSC, n ¼ 11) and examined the impact of these cellular subpopulations on the outcomes of patients following the same nonmyeloablative regimen. We hypothesized that the doses of CD34, CD3, CD4, CD8 or NK cells infused into BM recipients might have exerted an influence on donor chimerism. However, we found no statistically significant differences in the numbers of different cell subsets in association with chimerism outcomes. The numbers of the various cell subpopulations in the BM allograft also did not predict a response. The cell dose for each subset in the PBSC allograft was significantly higher than in the BM, but the numbers of infused CD34, CD3, CD4, CD8 or NK cells did not influence the incidence of GVHD or rates of remission in the PBSC recipients. However, after further analyzing according to the severity of acute GVHD in PBSC recipients, grades I and II vs grades III and IV, we found that the median CD34 cell dose was significantly higher in patients who developed grades III/IV GVHD compared to those developing grades I/II GVHD: median 19.1 Â 10 6 per kg (range, 6.5-24.4 Â 10 6 ) vs 9.65 Â 10 6 per kg (range, 2.06-12.2 Â 10 6 ; P ¼ 0.039).
Disease response and survival
In the BMT group, 20 out of 42 patients (48%) achieved a durable remission: CR, n ¼ 15; PR, n ¼ 5. In comparison, 8 out of 12 patients (60%) in the PBSC group obtained durable remission: CR, n ¼ 6; PR, n ¼ 2. There was no significant difference between the two groups in terms of remission rate. While there was a trend toward an improved PFS in the BM group relative to the PBSC group, this was not statistically significant and the overall survival between the two groups was essentially similar.
T-Cell recovery
Seven patients from the PBSC and 16 patients from the BM group, all with sustained, predominantly donor chimerism, were analyzed for T-cell reconstitution. As shown in Figure 4a , by 3 weeks, the recipients of PBSCT had 245784 CD4 cells per ml and 116741 CD8 cells per ml.
CD4
þ T-cell recovery was significantly higher in PBSCT than BMT recipients at 2 weeks with a median of 268 vs 18 CD4 cells per ml (Po0.05). At day 35, the CD4 cell counts were 312 per ml in PBSCT recipients vs 82 per ml in BMT recipients (Po0.05). The CD4 counts of PBSCT recipients were also significantly higher at day 90 (Po0.05). A significant difference in CD8 T-cell recovery was observed at day 14 with a median of 101 per ml in PBSCT recipients vs 13 per ml in BMT recipients (Po0.05), but not at later time points through day 90 (Figure 4b) . At 3 weeks posttransplant, the PBSCT recipients had a CD4:CD8 ratio X1.5, indicating early normalization of CD4:CD8 ratio. The number of CD4 þ CD45RA þ cells was also significantly higher at 2 weeks in the PBSCT group (median of 86 per ml) compared to BMT recipients (Po0.05). The rates of CMV reactivation were similar between the BM and PBSC groups: 9/20, 42% vs 4/12, 33%, respectively. There was also no significant difference between the two groups in terms of bacterial and fungal infections.
Discussion
The primary objective of this nonrandomized, retrospective study was to compare outcomes after transplantation with GCSF-mobilized PBSC and BM allografts following the same nonmyeloablative conditioning. Neutrophil and platelet engraftment occurred faster after allogeneic PBSCT than after BMT as has been uniformly reported to occur after myeloablative conditioning, [3] [4] [5] [6] 22, 23 with fewer patients requiring platelet and red cell transfusion in the PBSC group. The higher NC dose and CD34 þ cell content probably play a major role in promoting faster engraftment in the PBSC group. The rate of eventual graft loss was higher in the BM group relative to the PBSC group and prior autografting appears to be associated with sustained donor engraftment following BMT. We have demonstrated that a major mechanism of graft loss in these BMT recipients is host-derived T-cell-mediated immunologic rejection. 24 It is highly likely that the increased cell dose in the PBSC inoculum overcame host immune resistance and promoted donor engraftment. It is unknown at present which particular cell type(s) influenced engraftment, as the numbers of NCs, CD34
and NK cells were all significantly higher in PBSC compared to BM allografts.
The rate of conversion to FDC was significantly higher in PBSC recipients compared to the BMT group and this occurred faster in the PBSC group. While 13 out of 20 patients in the BM group achieved FDC gradually following DLI, 10 out of 12 in the PBSC group did so spontaneously and immediately post-transplant, precluding the administration of pDLI. The two groups were similar in terms of the rates of grade II-IV acute GVHD when analyzed according to the achievement of FDC, although there was an increased incidence of severe grade III and IV acute GVHD in the PBSC group compared with the BM group. These findings are consistent with the outcomes following myeloablative conditioning, in which most studies show a similar incidence of acute GVHD between the two groups. The lack of a significant difference in the incidence of acute GVHD despite the GCSF-mobilized PBSC allografts containing an approximately tenfold greater total number of T cells may be due to GCSF polarization of donor T cells toward Th 2 cytokine secretion (interleukin-4 (IL-4), IL-10), with reduced Th1 cytokine (IL-2, g-interferon production), an effect that is associated with less severe acute GVHD in animal models and clinical studies. 25, 26 GCSF treatment of healthy donors selectively increases the number of circulating Th2-inducing lymphoid dendritic cells (DC2), but not the number of Th1-inducing myeloid dendritic cells (DC1). 27, 28 There are also data suggesting that GCSF-induced protection against acute GVHD may be mediated through NK cells 29 and recently it has been shown that CD4 þ T cells exposed to GCSF may acquire the properties of regulatory cells that can prevent GVHD. 30, 31 The increased rates of chronic GVHD observed in our PBSC compared to BM recipients following identical nonmyeloablative conditioning are in keeping with several reports of a high incidence of chronic GVHD after myeloablative PBSCT. 3, 5, 23, 32, 33 Possible explanations for the increased incidence of chronic GVHD following PBSCT include the larger numbers of CD34 þ cells and T cells in the infused inoculum [34] [35] [36] [37] [38] and the skewed cytokine profile, namely polarization of donor T cells toward a Th2 phenotype. 25, 26 The sources of allografts, BM vs PBSC, not only differed with regard to CD34 þ cell dose, but the GCSF-mobilized PBSC graft contained 4-to 20-fold more T cells, NK cells and B cells. In BM recipients, we found no significant correlation between the numbers of different cell subsets and the ultimate fate of donor chimerism (i.e., sustained chimerism vs loss of allograft) or disease response. The doses of infused CD34, CD3, CD4, CD8 or NK cells did not appear to influence the GVHD or remission rates in the PBSC recipients. However, a higher CD34
þ cell dose was associated with increased risk of severe GVHD in the PBSC group as the median number of CD34 þ cell dose was significantly higher in patients who developed grades III/IV GVHD compared to those developing grades I/II GVHD. While increasing CD34 þ cell dose has been associated with faster hematopoietic reconstitution, higher doses of CD34 þ PBSC have been found to be associated with a poorer outcome, mainly due to increased GVHD-related mortality. [36] [37] [38] PBSC recipients achieved a significantly greater CD4 and CD8 T-cell recovery early post-transplant compared to BM recipients.
The circulating numbers of naive CD4 þ CD45RA þ cells were also significantly higher early post-transplant in the PBSC group. This finding is consistent with two reports that showed faster T-cell recovery in PBSC recipients compared with the BM recipients after myeloablative conditioning. 39, 40 The differences in favor of PBSCT can be explained, at least in part, by the transfer of a very high number of donor T cells, which have a life span of months to years. [41] [42] [43] The increased number of CD34 þ cells in PBSC allografts may also contribute to improved immune reconstitution. [44] [45] [46] With respect to infectious complications such as CMV reactivation, bacterial and fungal infections, we could not find a significant difference between the two groups although this might have been influenced by the small number of patients particularly in PBSC group.
In conclusion, PBSCT when compared with BMT following the same cyclophosphamide and equine ATGbased nonmyeloablative conditioning leads to faster neutrophil and platelet engraftment, significantly reduced transfusion requirements, a lower incidence of graft failure, faster T-cell recovery, a higher incidence of spontaneous near-full or FDC as well as an increased incidence of acute and chronic GVHD, thus precluding the majority of patients from receiving pDLI. In PBSC recipients, a high number of CD34 þ cells is associated with a high incidence of severe, grade III-IV acute GVHD. As the number of patients and the heterogeneity of diseases did not allow for a comparison of response rates and survival, further prospective studies are warranted to address these outcomes.
